Fertility warning
This medicine may affect fertility.
Leaflet CABAZITAXEL AQVIDA 20mg / ml concentrate for solution for infusion
- Product code:
- W71784001
- Quantity:
- 1
- Indicated for:
- prostate cancer
- Route of administration:
- infusion
- Substance:
- cabazitaxel (taxane antineoplastic)
- ATC
- L01CD04 — Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Taxanes
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Cabazitaxel is a medication used for the treatment of metastatic castration-resistant prostate cancer, particularly in patients previously treated with docetaxel. It is a chemotherapeutic agent from the taxane class that interferes with microtubule function, inhibiting cell division and causing cancer cell death.
The medication is administered via intravenous infusion, usually once every three weeks, in combination with prednisone, as directed by a doctor. The treatment requires close monitoring to manage side effects and assess the patient's response.
Common side effects include fatigue, nausea, diarrhea, decreased blood cell counts, and hair loss. In rare cases, severe adverse effects such as febrile neutropenia or allergic reactions may occur.
Cabazitaxel is not recommended for pregnant or breastfeeding women. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
The medication is administered via intravenous infusion, usually once every three weeks, in combination with prednisone, as directed by a doctor. The treatment requires close monitoring to manage side effects and assess the patient's response.
Common side effects include fatigue, nausea, diarrhea, decreased blood cell counts, and hair loss. In rare cases, severe adverse effects such as febrile neutropenia or allergic reactions may occur.
Cabazitaxel is not recommended for pregnant or breastfeeding women. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
General data about CABAZITAXEL AQVIDA 20mg / ml
- Substance:
- cabazitaxel
- Date of latest medicines list:
- 01-04-2026
- Product code:
- W71784001
- Concentration:
- 20mg / ml
- Pharmaceutical form:
- concentrate for solution for infusion
- Quantity:
- 1
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for cabazitaxel
Concentrations available for cabazitaxel
- 10mg/ml
- 20mg/ml
- 60mg